Bellevue Group Ag Exelixis, Inc. Transaction History

Bellevue Group Ag

$5.98 Billion
Q2 2024

A detailed history of Bellevue Group Ag transactions in Exelixis, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 1,803,200 shares of EXEL stock, worth $46.8 Million. This represents 0.68% of its overall portfolio holdings.

Number of Shares

1,803,200

Previous 1,903,200 5.25%

Holding current value

$46.8 Million

Previous $45.2 Million 10.29%

% of portfolio

0.68%

Previous 0.71%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $2.03 Million - $2.37 Million	-100,000 Reduced 5.25%	1,803,200 $40.5 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $4.13 Million - $4.9 Million	-204,900 Reduced 9.72%	1,903,200 $45.2 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $5.16 Million - $6.46 Million	-267,825 Reduced 11.27%	2,108,100 $50.6 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $3.01 Million - $3.59 Million	-158,075 Reduced 6.24%	2,375,925 $51.9 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $1.36 Million - $1.54 Million	-75,000 Reduced 2.87%	2,534,000 $48.4 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $1.05 Million - $1.25 Million	-64,500 Reduced 2.41%	2,609,000 $50.6 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $78,400 - $111,350	-5,000 Reduced 0.19%	2,673,500 $41.9 Million
Q2 2022 Aug 11, 2022	SELL	$17.44 - $23.16 $706,320 - $937,980	-40,500 Reduced 1.49%	2,678,500 $55.8 Million
Q1 2022 May 13, 2022	SELL	$17.03 - $22.67 $2.38 Million - $3.17 Million	-140,000 Reduced 4.9%	2,719,000 $61.6 Million
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $1.19 Million - $1.54 Million	-73,000 Reduced 2.49%	2,859,000 $60.4 Million
Q2 2021 Aug 12, 2021	SELL	$17.95 - $25.56 $224,375 - $319,500	-12,500 Reduced 0.42%	2,932,000 $53.4 Million
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $2.37 Million - $3.2 Million	-129,000 Reduced 4.2%	2,944,500 $59.1 Million
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $537,420 - $700,440	26,000 Added 0.85%	3,073,500 $75.1 Million
Q2 2020 Aug 13, 2020	SELL	$16.46 - $27.42 $15.3 Million - $25.4 Million	-927,900 Reduced 23.34%	3,047,500 $72.3 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $646,362 - $974,460	44,700 Added 1.14%	3,975,400 $68.5 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $1.09 Million - $1.36 Million	72,000 Added 1.87%	3,930,700 $69.3 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $355,368 - $455,265	-20,100 Reduced 0.52%	3,858,700 $68.2 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $70.8 Million - $92.5 Million	3,738,300 Added 2660.71%	3,878,800 $82.9 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $911,400 - $1.15 Million	46,500 Added 49.47%	140,500 $3.34 Million
Q4 2018 Feb 12, 2019	BUY	$13.65 - $21.8 $1.28 Million - $2.05 Million	94,000 New	94,000 $1.85 Million
Q2 2018 Aug 07, 2018	SELL	$18.56 - $22.45 $924,287 - $1.12 Million	-49,800 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$22.15 - $31.89 $17,720 - $25,512	-800 Reduced 1.58%	49,800 $1.1 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $33,922 - $43,302	-1,400 Reduced 2.69%	50,600 $1.54 Million
Q2 2017 Aug 14, 2017	BUY	N/A	52,000	52,000 $1.28 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.35B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Exelixis, Inc. Transaction History